Pardeep S. Jhund

Generating author description...

All published works

Action	Title	Year	Authors
+	Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials	2024	Pablo-Miki Martí Castellote Christopher Reeder Brian Claggett Pulkit Singh Emily S. Lau Shaan Khurshid Puneet Batra Steven A. Lubitz Mahnaz Maddah Orly Vardeny
+	Evaluating Tools for Assessing Bias in a Meta-Analysis of Clinical Trials on Race and RAS Blockade—Reply	2024	Li Shen Pardeep S. Jhund John J.V. McMurray
+ PDF Chat	A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials	2024	Toru Kondo Pardeep S. Jhund Samvel B. Gasparyan Mingming Yang Brian Claggett Finnian R. McCausland Paolo Tolomeo Muthiah Vadagunathan Hiddo J.L. Heerspink Scott D. Solomon
+	Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER	2023	Ankeet S. Bhatt Daniel Lindholm A.A. Nilsson Natalia Zaozerska Brian Claggett Muthiah Vaduganathan Mikhail Kosiborod Carolyn S.P. Lam Adrian F. Hernandez Felipe A. Martínez
+ PDF Chat	Within trial comparison of survival time projections from short‐term follow‐up with long‐term follow‐up findings	2022	João Pedro Ferreira Brian Claggett Kieran F. Docherty Pardeep S. Jhund Faı̈ez Zannad Scott D. Solomon John J.V. McMurray
+ PDF Chat	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes	2022	Brian Claggett Zachary R. McCaw Lü Tian John J.V. McMurray Pardeep S. Jhund Hajime Uno Marc A. Pfeffer Scott D. Solomon L. J. Wei
+	Estimating the Lifetime Benefits of Treatments for Heart Failure	2020	João Pedro Ferreira Kieran F. Docherty Susan Stienen Pardeep S. Jhund Brian Claggett Scott D. Solomon Mark C. Petrie John Gregson Stuart J. Pocock Faı̈ez Zannad
+	Use of the Win Ratio in Cardiovascular Trials	2020	João Pedro Ferreira Pardeep S. Jhund Kévin Duarte Brian Claggett Scott D. Solomon Stuart J. Pocock Mark C Petrie Faı̈ez Zannad John J.V. McMurray
+ PDF Chat	Association is not causation: treatment effects cannot be estimated from observational data in heart failure	2018	Christopher Rush Ross T. Campbell Pardeep S. Jhund Mark C. Petrie John J.V. McMurray
+	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits	2017	Li Shen Pardeep S. Jhund Ulrik M. Mogensen Lars Køber Brian Claggett Jennifer K. Rogers John J.V. McMurray
+ PDF Chat	How robust are clinical trials in heart failure?	2016	Kieran F. Docherty Ross T. Campbell Pardeep S. Jhund Mark C. Petrie John J.V. McMurray
+ PDF Chat	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure	2016	Ross T. Campbell G. Willox Pardeep S. Jhund Nathaniel M. Hawkins Flora Huang Mark C. Petrie John J.V. McMurray
+	Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations	2014	Jennifer K. Rogers Pardeep S. Jhund Ana Cristina Perez Moreno Michael Böhm John G.F. Cleland Lars Gullestad John Kjekshus Dirk J. van Veldhuisen John Wikstrand Hans Wedel

Common Coauthors

Coauthor	Papers Together
John J.V. McMurray	13
Brian Claggett	8
Scott D. Solomon	6
Mark C. Petrie	4
Ross T. Campbell	3
Stuart J. Pocock	3
Kieran F. Docherty	3
Faı̈ez Zannad	3
João Pedro Ferreira	3
Li Shen	2
Akshay S. Desai	2
Jennifer K. Rogers	2
John G.F. Cleland	1
Paolo Tolomeo	1
John Wikstrand	1
Lars Gullestad	1
John Gregson	1
Eldrin F. Lewis	1
John Kjekshus	1
Marc A. Pfeffer	1
Hiddo J.L. Heerspink	1
Rudolf A. de Boer	1
Emily S. Lau	1
Zachary R. McCaw	1
Lars Køber	1
Finnian R. McCausland	1
Felipe A. Martínez	1
Samvel B. Gasparyan	1
Susan Stienen	1
Shaan Khurshid	1
Steven A. Lubitz	1
Nathaniel M. Hawkins	1
Ulrik M. Mogensen	1
Mikhail Kosiborod	1
Pablo-Miki Martí Castellote	1
Kévin Duarte	1
Flora Huang	1
Ankeet S. Bhatt	1
Muthiah Vaduganathan	1
Carolyn S.P. Lam	1
Christopher Rush	1
Dirk J. van Veldhuisen	1
Patrick T. Ellinor	1
Toru Kondo	1
Magnus Petersson	1
Natalia Zaozerska	1
Daniel Lindholm	1
Hajime Uno	1
Jonathan W. Cunningham	1
Mahnaz Maddah	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <scp>CHARM</scp>‐Preserved	2013	Jennifer K. Rogers Stuart J. Pocock John J.V. McMurray Christopher B. Granger Eric L. Michelson Jan Östergren Marc A. Pfeffer Scott D. Solomon Karl Swedberg Salim Yusuf	3
+ PDF Chat	The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities	2011	SJ Pocock Cono Ariti Timothy Collier Dee Dee Wang	3
+	Nonparametric Analysis of Recurrent Events and Death	2000	Debashis Ghosh D. Y. Lin	2
+ PDF Chat	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis	2014	Hajime Uno Brian Claggett Lü Tian Eisuke Inoue Paul Gallo Toshio Miyata Deborah Schrag Masahiro Takeuchi Yoshiaki Uyama Lihui Zhao	2
+ PDF Chat	The ASA Statement on <i>p</i>-Values: Context, Process, and Purpose	2016	Ronald L. Wasserstein Nicole A. Lazar	2
+	Cox's Regression Model for Counting Processes: A Large Sample Study	1982	P. Andersen Richard D. Gill	1
+ PDF Chat	Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research	2013	Nick Freemantle Louise Marston Kate Walters John Wood Matthew R. Reynolds Irene Petersen	1
+ PDF Chat	Semiparametric Regression for the Mean and Rate Functions of Recurrent Events	2000	D. Y. Lin L. J. Wei Ilsoon Yang Z. Ying	1
+	The Robust Inference for the Cox Proportional Hazards Model	1989	D. Y. Lin L. J. Wei	1
+	Combining mortality and longitudinal measures in clinical trials	1999	Dianne M. Finkelstein David Schoenfeld	1
+ PDF Chat	Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials	2007	Ignacio Ferreira‐González Gaiet Permanyer-Miralda Antònia Domingo‐Salvany Jason W. Busse Diane Heels‐Ansdell Víctor M. Montori Elie A. Akl Dianne Bryant Pablo Alonso‐Coello Jordi Alonso	1
+	Misspecified proportional hazard models	1986	C. A. Struthers John D. Kalbfleisch	1
+ PDF Chat	Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome	2013	Patrick Royston Mahesh Parmar	1
+ PDF Chat	The Number of Patients and Events Required to Limit the Risk of Overestimation of Intervention Effects in Meta-Analysis—A Simulation Study	2011	Kristian Thorlund Georgina Imberger Michael Walsh Rong Chu Christian Gluud Jørn Wetterslev Gordon Guyatt P.J. Devereaux Lehana Thabane	1
+	Statistical significance and fragility criteria for assessing a difference of two proportions	1991	Stephen D. Walter	1
+	Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity	2013	Soo Young Kim Ji Eun Park Yoon Jae Lee Hyun‐Ju Seo Seung Soo Sheen Seokyung Hahn Bo‐Hyoung Jang Hee Jung Son	1
+	Bias and causal associations in observational research	2002	David A. Grimes Kenneth F. Schulz	1
+	Sample size slippages in randomised trials: exclusions and the lost and wayward	2002	Kenneth F. Schulz David A. Grimes	1
+	Zero-Inflated Poisson Regression, with an Application to Defects in Manufacturing	1992	Diane Lambert	1
+ PDF Chat	Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey	2011	Elke Vervölgyi Mandy Kromp Guido Skipka Ralf Bender Thomas Kaiser	1
+	Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group	1998	Ralph B. D’Agostino	1
+ PDF Chat	Invited Commentary: Assessing Treatment Effects by Using Observational Analyses--Opportunities and Limitations	2009	P. S. Wang M. Schoenbaum	1
+	Opportunities and challenges of combined effect measures based on prioritized outcomes	2013	Geraldine Rauch Antje Jahn‐Eimermacher Werner Brannath Meinhard Kieser	1
+ PDF Chat	The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials	2001	David Moher Kenneth F. Schulz Douglas G. Altman	1
+	The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials	2001	David Moher	1
+ PDF Chat	Key Issues in End Point Selection for Heart Failure Trials: Composite End Points	2005	James D. Neaton Gerry Gray Bram D. Zuckerman Marvin A. Konstam	1
+	Quality adjusted survival analysis	1990	Paul Glasziou R. John Simes Richard D. Gelber	1
+	Estimating Treatment Effects Using Observational Data	2007	Ralph B. D’Agostino	1
+	The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index	2014	Michael Walsh Sadeesh Srinathan Daniel F. McAuley Marko Mrkobrada Oren Levine Christine Ribic Amber O. Molnar Neil D. Dattani Andrew Burke Gordon Guyatt	1
+	Empirical estimation of life expectancy from large clinical trials: Use of left‐truncated, right‐censored survival analysis methodology	2008	Charlotte Nelson Jie Sun Anastasios A. Tsiatis Daniel B. Mark	1
+	Making Sense of Statistics in Clinical Trial Reports	2015	Stuart J. Pocock John J.V. McMurray Timothy Collier	1
+	Introduction to the Analysis of Survival Data in the Presence of Competing Risks	2016	Peter C. Austin Douglas S. Lee Jason P. Fine	1
+	From Methods to Policy: Observational studies versus randomized trials: squaring off	2012	Sheldon Greenfield Sherrie H. Kaplan	1
+ PDF Chat	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency	2016	Stefan D. Anker Stefan Schroeder Dan Atar Jeroen J. Bax Claudio Ceconi Martín Cowie Adam Crisp Fabienne Dominjon Ian Ford Hossein A. Ghofrani	1
+	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring	2016	Julien Péron Marc Buyse Brice Ozenne Laurent Roche Pascal Roy	1
+	On the win-ratio statistic in clinical trials with multiple types of event	2016	David Oakes	1
+	A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components	2016	Gaohong Dong Di Li Steffen Ballerstedt Marc Vandemeulebroecke	1
+ PDF Chat	Quantifying the totality of treatment effect with multiple event‐time observations in the presence of a terminal event from a comparative clinical study	2018	Brian Claggett Lü Tian Haoda Fu Scott D. Solomon L. J. Wei	1
+ PDF Chat	Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review	2017	Adam Streeter Nan Lin Louise Crathorne Marcela Haasova Christopher Hyde David Melzer William Henley	1
+	Randomized Clinical Trials	1976	David P. Byar Richard Simon William T. Friedewald James J. Schlesselman David L. DeMets Jonas H. Ellenberg Mitchell H. Gail James H. Ware	1
+	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials	2018	Brian Claggett Stuart J. Pocock L. J. Wei Marc A. Pfeffer John J.V. McMurray Scott D. Solomon	1
+	Graphing the Win Ratio and its components over time	2018	Dianne M. Finkelstein David Schoenfeld	1
+	Limitations of hazard ratios in clinical trials	2018	Mats Julius Stensrud John M. Aalen Odd O. Aalen Morten Valberg	1
+	The Win Ratio: On Interpretation and Handling of Ties	2019	Gaohong Dong David C. Hoaglin Junshan Qiu Roland Matsouaka Yu‐Wei Chang Jiuzhou Wang Marc Vandemeulebroecke	1
+	Statistical Appraisal of 6 Recent Clinical Trials in Cardiology	2019	Stuart J. Pocock Timothy Collier	1
+ PDF Chat	Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease	2019	Edward F. Vonesh Hocine Tighiouart Jian Ying Hiddo J.L. Heerspink Julia B. Lewis Natalie Staplin Lesley A. Inker Tom Greene	1
+ PDF Chat	Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies	2019	Zachary R. McCaw Guosheng Yin Lee‐Jen Wei	1
+	On the empirical choice of the time window for restricted mean survival time	2020	Lü Tian Hua Jin Hajime Uno Ying Lü Bo Huang Keaven M. Anderson L. J. Wei	1
+ PDF Chat	Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses	2020	Stefan Schandelmaier Matthias Briel Ravi Varadhan Christopher H. Schmid Niveditha Devasenapathy Rodney A. Hayward Joel Gagnier Michael Borenstein Geert J. M. G. van der Heijden Issa J Dahabreh	1
+	The win ratio approach for composite endpoints: practical guidance based on previous experience	2020	Björn Redfors John Gregson Aaron Crowley Thomas McAndrew Ori Ben‐Yehuda Gregg W. Stone Stuart J. Pocock	1